Floatz logo

Z/E 4-HYDROXY TAMOXIFEN

Invasive Breast Carcinoma

Northwestern UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

58 Active assets in the Invasive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
University of California, San Francisco
Phase 4BBB
Letrozole
Emory University
Phase 4BBB
Arimidex
Jonsson Comprehensive Cancer Center
Phase 4BBB
EXEMESTANE
University of California, San Francisco
Phase 4BBB
TRASTUZUMAB
Massachusetts General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Z/E 4-HYDROXY TAMOXIFEN is also rated in:

ductal breast carcinoma in situDormant
B
Indicative ·
62 / 100
View asset →
estrogen-receptor positive breast cancerDormant
B
Indicative ·
62 / 100
View asset →
Mammographically Dense BreastDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →